Clinical Trial Update: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma

View source ↗

Summary

An observational study of Rituximab (MabThera/Rituxan) in patients with follicular lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphoma, Follicular | Status: TERMINATED